You have accessJournal of UrologyImaging/Radiology: Uroradiology II1 Apr 2018MP20-17 CENTRAL ABDOMINAL UPTAKE ON INDIUM-111 CAPROMAB PENDETIDE IMAGING: A POWERFUL PROGNOSTIC INDICATOR FOR PROSTATE CANCER IN HIGH-RISK PATIENTS AND IN THE SETTING OF BIOCHEMICAL RECURRENCE Goran Rac, Shepherd Caitlin, Sarah Starosta, Barry Keane, Sam Keane, William Rieter, and Thomas Keane Goran RacGoran Rac More articles by this author , Shepherd CaitlinShepherd Caitlin More articles by this author , Sarah StarostaSarah Starosta More articles by this author , Barry KeaneBarry Keane More articles by this author , Sam KeaneSam Keane More articles by this author , William RieterWilliam Rieter More articles by this author , and Thomas KeaneThomas Keane More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.687AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Indium-111 Capromab Pendetide (ProstaScint) is a monoclonal PSMA-based imaging modality used at our institution for the evaluation of newly diagnosed high-risk prostate cancer and in patients with biochemical recurrence after definitive treatment. Central abdominal update (CAU) on ProstaScint has been found to be a poor prognostic indicator; however, there is a paucity of long term data on the subject. We present over 10 years' experience utilizing ProstaScint to assess the relationship between CAU and prostate cancer treatment failure. METHODS We performed a retrospective analysis of 187 patients diagnosed with CAU on ProstaScint scan obtained for either high-risk prostate cancer or evaluation for salvage therapy between December 2003 and December 2011. A total of 50 patients with long term follow-up were identified. Of these, 36 patients underwent salvage therapy after biochemical recurrence. The remaining 14 patients underwent Prostascint scan for high-risk prostate cancer prior to primary intervention. There was a mean length of follow up of 8.6 years. RESULTS Overall, 86% (43/50) of patients with CAU failed either primary or salvage treatment of prostate cancer. Half (7/14) of the patients with CAU on a scan for high-risk prostate cancer prior to undergoing primary intervention failed initial treatment. All 36 patients scanned for biochemical recurrence failed salvage treatment. Average time to recurrence after initial or salvage treatment was 3.6 years, with 67.4% (29/43) of patients with early recurrence less than 3 years after treatment. Over half (26/50) of patients with CAU required subsequent radiation therapy: 9 undergoing radiation alone and 17 undergoing combined radiation and androgen depravation therapy with treatment failures of 100% (9/9) and 76.6% (13/17), respectively. 89.2% (33/37) of patients with 5-year follow-up had treatment failure. All 19 patients with 10-year follow-up had treatment failure. CONCLUSIONS In our cohort of patients, the presence of CAU on Prostascint imaging correlated with failure of both primary and salvage interventions. Patients with CAU had an earlier time to recurrence. The majority of patients at 5 years and all patients at 10 years failed prostate cancer treatment. We confirm that CAU on Prostascint imaging is associated with poor outcomes and responses to both primary and salvage therapy. Imaging with ProstaScint should be considered in patients with high-risk prostate cancer as well as those with biochemical recurrence prior to salvage therapies. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e260 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Goran Rac More articles by this author Shepherd Caitlin More articles by this author Sarah Starosta More articles by this author Barry Keane More articles by this author Sam Keane More articles by this author William Rieter More articles by this author Thomas Keane More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...